Senores Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
SENORES
Pharmaceuticals
Share Price NSE
₹916.70
▼
-23.05 (-2.45%)
Share Price BSE
₹917.30
▼
-20.80 (-2.22%)
As of April 28, 2026, the Senores Pharmaceuticals share price (NSE: SENORES) is ₹916.70 on NSE and ₹917.30 on BSE, down 2.45% from the previous close, with shares trading between ₹911.00 and ₹947.70, and a 52-week range of ₹483.75–₹939.75.
Browse SENORES complete financial to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Senores Pharmaceuticals Market Cap
₹4,116.50 Cr.
SENORES P/E Ratio (TTM)
39.88
Senores Pharmaceuticals P/B Ratio
5.04
EPS (TTM)
₹16.12
Dividend Yield
-
Debt to Equity
0.58
SENORES 52 Week High
₹939.75
Senores Pharmaceuticals 52 Week Low
₹483.75
Operating Margin
27.00%
Profit Margin
20.12%
SENORES Revenue (TTM)
₹169.00
EBITDA
₹48.00
Net Income
₹34.00
Total Assets
₹1,227.00
Total Equity
₹812.00
Senores Pharmaceuticals Share Price History - Stock Screener Chart
Screen SENORES historical share price movements with interactive charts. Analyze price trends and patterns.
Senores Pharmaceuticals Company Profile - Fundamental Screener
Screen Senores Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for SENORES shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE0RB801010
Senores Pharmaceuticals Balance Sheet Screener
Screen SENORES balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Assets | ||||
| Total Assets | 1,227 | 622 | 131 | 59 |
| Current Assets | 722 | 251 | 51 | 27 |
| Fixed Assets | 301 | 235 | 27 | 7 |
| Liabilities | ||||
| Total Liabilities | 0 | 0 | 0 | 0 |
| Current Liabilities | 174 | 143 | 34 | 13 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||
| Total Equity | 812 | 232 | 46 | 37 |
| Share Capital | 46 | 31 | 10 | 9 |
| Reserves & Surplus | 740 | 174 | 36 | 28 |
Senores Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Senores Pharmaceuticals income statement and profit fundamentals.
Analyze SENORES quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Senores Pharmaceuticals share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 169 | 159 | 134 | 117 | 108 | 100 | 80 | 104 | 80 |
| Expenses | 121 | 112 | 104 | 95 | 77 | 77 | 59 | 80 | 64 |
| EBITDA | 48 | 47 | 30 | 22 | 31 | 23 | 21 | 24 | 16 |
| Operating Profit % | 27.00% | 27.00% | 20.00% | 10.00% | 25.00% | 21.00% | 26.00% | 22.00% | 19.00% |
| Depreciation | 8 | 8 | 6 | 5 | 4 | 4 | 4 | 4 | 3 |
| Interest | 5 | 6 | 5 | 5 | 6 | 5 | 5 | 3 | 3 |
| Profit Before Tax | 45 | 41 | 27 | 21 | 21 | 16 | 14 | 18 | 10 |
| Tax | 11 | 11 | 5 | 3 | 4 | 3 | 3 | 3 | 3 |
| Net Profit | 34 | 30 | 21 | 18 | 16 | 13 | 11 | 14 | 7 |
| EPS | 7.29 | 6.54 | 4.60 | 3.81 | 5.04 | 3.92 | 3.39 | 8.03 | 4.01 |
Senores Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen SENORES cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March |
|---|---|---|---|---|
| Operating Activities | -46 | -26 | -1 | -10 |
| Investing Activities | -430 | -54 | -48 | -24 |
| Financing Activities | 573 | 87 | 46 | 37 |
| Net Cash Flow | 98 | 8 | -3 | 2 |
Senores Pharmaceuticals Shareholding Pattern Screener
See Senores Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Senores Pharmaceuticals promoter holding and ownership changes for SENORES on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Jul | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 45.82% | 45.77% | 45.78% | 45.80% | 45.80% | 66.66% | 45.76% | 45.76% |
| FII Holding | 3.64% | 4.17% | 3.67% | 4.28% | 3.35% | 0.00% | 5.51% | 4.25% |
| DII Holding | 9.61% | 9.65% | 9.51% | 8.61% | 9.31% | 0.00% | 18.61% | 11.78% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 31.64% | 31.43% | 31.44% | 31.09% | 31.94% | 0.00% | 27.88% | 28.71% |
| Other Holding | 9.30% | 8.97% | 9.60% | 10.22% | 9.59% | 33.34% | 2.23% | 9.49% |
| Shareholder Count | 34,126 | 37,653 | 36,389 | 34,917 | 34,401 | 177 | 43,707 | 43,707 |
Senores Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Senores Pharmaceuticals dividend history with payout and yield data.
View Senores Pharmaceuticals dividend details including ex-dates and amounts for SENORES stock.
Senores Pharmaceuticals Stock Index Membership
See which indices include Senores Pharmaceuticals stock.
Check SENORES index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE INDEX BSE HC
BSE INDEX BSEIPO
BSE INDEX SMLCAP
NIFTY IPO
Senores Pharmaceuticals Market Events Screener - Corporate Actions
Get Senores Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Senores Pharmaceuticals stock events that may affect SENORES share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -3.98% | ||
| 2026-01-31 | 2026-01-31 | Extraordinary General Meeting | NA | -6.84% |
| 2026-01-20 | 2026-01-20 | Quarterly Result Announcement | NA | -0.71% |
| 2025-11-06 | 2025-11-06 | Quarterly Result Announcement | NA | -2.12% |
| 2025-07-23 | 2025-07-23 | Quarterly Result Announcement | NA | -0.19% |
| 2025-05-15 | 2025-05-15 | Quarterly Result Announcement | NA | 11.84% |
| 2025-01-23 | 2025-01-23 | Quarterly Result Announcement | NA | -6.09% |
Senores Pharmaceuticals Competitors Screener - Peer Comparison
Screen SENORES competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 402,009 | 37.09 | 54,729 | 9.71% | 10,980 | 40.43 |
| Divis Laboratories | 165,360 | 67.44 | 9,712 | 18.67% | 2,191 | 57.69 |
| Torrent Pharmaceuticals | 141,453 | 61.91 | 11,539 | 6.99% | 1,911 | 49.92 |
| Lupin | 106,313 | 22.78 | 22,910 | 13.74% | 3,306 | 54.90 |
| Dr Reddys Laboratories | 103,137 | 18.46 | 33,741 | 16.73% | 5,725 | 47.42 |
| Cipla | 100,229 | 21.93 | 28,410 | 7.12% | 5,291 | 46.80 |
| Zydus Life Science | 94,983 | 18.80 | 23,511 | 18.55% | 4,615 | 64.41 |
| Mankind Pharma | 87,721 | 48.18 | 12,744 | 20.90% | 2,007 | 56.81 |
| Aurobindo Pharma | 80,499 | 23.10 | 32,346 | 9.43% | 3,484 | 70.15 |
| Alkem Laboratories | 66,741 | 27.48 | 13,458 | 3.70% | 2,216 | 59.02 |
Senores Pharmaceuticals Company Announcements - News Screener
Screen SENORES latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-04-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-04-03 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-04-01 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-28 | Announcement under Regulation 30 (LODR)-Allotment | - |
| 2026-03-28 | Board Meeting Outcome for Outcome Of Board Meeting Held On March 28 2026 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-03-17 | Intimation Regarding Changes In The Senior Management Personnel (SMP) Of The Company | - |
| 2026-03-12 | Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-03-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-03 | Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-03 | Announcement Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-03-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-02 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-17 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-17 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-17 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-17 | Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations 2011. | - |
| 2026-02-13 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-02-04 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |